{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:43:20Z","timestamp":1793234600556,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02162-y","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T02:04:31Z","timestamp":1778983471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of pathologic complete response in triple\u2011negative breast cancer treated with neoadjuvant chemotherapy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6376-097X","authenticated-orcid":false,"given":"Xingyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"2162_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181\u2013204. https:\/\/doi.org\/10.1146\/annurev-pathol-042420-093238.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2162_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2162_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-013-2421-5","volume":"138","author":"S Bayraktar","year":"2013","unstructured":"Bayraktar S, Gl\u00fcck S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2013;138(1):21\u201335. https:\/\/doi.org\/10.1007\/s10549-013-2421-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2162_CR4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1245\/s10434-015-4402-x","volume":"22","author":"AK Garg","year":"2015","unstructured":"Garg AK, Buchholz TA. Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol. 2015;22(5):1434\u201340. https:\/\/doi.org\/10.1245\/s10434-015-4402-x.","journal-title":"Ann Surg Oncol"},{"key":"2162_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102852","volume":"132","author":"C Corti","year":"2025","unstructured":"Corti C, Binbo\u011fa Kurt B, Koca B, et al. Estrogen signaling in early-stage breast cancer: impact on neoadjuvant chemotherapy and immunotherapy. Cancer Treat Rev. 2025;132:102852. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102852.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2162_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0.","journal-title":"J Hematol Oncol"},{"key":"2162_CR7","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.2147\/DDDT.S253961","volume":"14","author":"H Wang","year":"2020","unstructured":"Wang H, Mao X. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des Devel Ther. 2020;14:2423\u201333. https:\/\/doi.org\/10.2147\/DDDT.S253961.","journal-title":"Drug Des Devel Ther"},{"key":"2162_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674. https:\/\/doi.org\/10.1136\/bmj-2022-071674.","journal-title":"BMJ"},{"issue":"2","key":"2162_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, et al. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21(2):135\u201348. https:\/\/doi.org\/10.1080\/14737140.2021.1840984.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"2162_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"15","key":"2162_CR11","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2162_CR12","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-025-17081-7","volume":"32","author":"LM Perry","year":"2025","unstructured":"Perry LM, Sevilimedu V, Polidorio N, et al. Predictors of pathologic complete response with neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. Ann Surg Oncol. 2025;32(6):3991\u20134001. https:\/\/doi.org\/10.1245\/s10434-025-17081-7.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2162_CR13","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.3892\/ol.2017.6692","volume":"14","author":"A Nakashoji","year":"2017","unstructured":"Nakashoji A, Matsui A, Nagayama A, et al. Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Lett. 2017;14(4):4135\u201341. https:\/\/doi.org\/10.3892\/ol.2017.6692.","journal-title":"Oncol Lett"},{"issue":"1","key":"2162_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13058-025-01994-y","volume":"27","author":"M Li","year":"2025","unstructured":"Li M, Zhou S, Lv H, et al. Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations. Breast Cancer Res. 2025;27(1):41. https:\/\/doi.org\/10.1186\/s13058-025-01994-y.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2162_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00280-010-1371-4","volume":"67","author":"H Masuda","year":"2011","unstructured":"Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 2011;67(4):911\u20137. https:\/\/doi.org\/10.1007\/s00280-010-1371-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2162_CR16","doi-asserted-by":"publisher","first-page":"1570394","DOI":"10.3389\/fimmu.2025.1570394","volume":"16","author":"X Chen","year":"2025","unstructured":"Chen X, Ye H, Xu D, et al. Pathological complete response and prognostic predictive factors of neoadjuvant chemoimmunotherapy in early stage triple-negative breast cancer. Front Immunol. 2025;16:1570394. https:\/\/doi.org\/10.3389\/fimmu.2025.1570394.","journal-title":"Front Immunol"},{"issue":"2","key":"2162_CR17","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/bcr2834","volume":"13","author":"B Keam","year":"2011","unstructured":"Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22. https:\/\/doi.org\/10.1186\/bcr2834.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2162_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae025","volume":"29","author":"C Wang","year":"2024","unstructured":"Wang C, Shi Q, Zhang G, et al. Two hematological markers predicting the efficacy and prognosis of neoadjuvant chemotherapy using Lobaplatin against triple-negative breast cancer. Oncologist. 2024;29(5):e635-e642. https:\/\/doi.org\/10.1093\/oncolo\/oyae025.","journal-title":"Oncologist"},{"issue":"3","key":"2162_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4048\/jbc.2016.19.3.261","volume":"19","author":"YY Jung","year":"2016","unstructured":"Jung YY, Hyun CL, Jin MS, et al. Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. J Breast Cancer. 2016;19(3):261\u20137. https:\/\/doi.org\/10.4048\/jbc.2016.19.3.261.","journal-title":"J Breast Cancer"},{"key":"2162_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.breast.2016.05.013","volume":"32","author":"F Karatas","year":"2017","unstructured":"Karatas F, Erdem GU, Sahin S, et al. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast. 2017;32:237\u201344. https:\/\/doi.org\/10.1016\/j.breast.2016.05.013.","journal-title":"Breast"},{"issue":"4","key":"2162_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4103\/ijc.IJC_238_17","volume":"54","author":"S Subbiah","year":"2017","unstructured":"Subbiah S, Gopu G, Senthilkumar P, et al. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. Indian J Cancer. 2017;54(4):652\u20137. https:\/\/doi.org\/10.4103\/ijc.IJC_238_17.","journal-title":"Indian J Cancer"},{"issue":"Suppl 1","key":"2162_CR22","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1007\/s12032-010-9742-6","volume":"28","author":"XR Li","year":"2011","unstructured":"Li XR, Liu M, Zhang YJ, et al. CK5\/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 2011;28(Suppl 1):S129\u201334. https:\/\/doi.org\/10.1007\/s12032-010-9742-6.","journal-title":"Med Oncol"},{"issue":"6","key":"2162_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s12282-023-01504-y","volume":"30","author":"H Kusama","year":"2023","unstructured":"Kusama H, Kittaka N, Soma A, et al. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer. Breast Cancer. 2023;30(6):1085\u201393. https:\/\/doi.org\/10.1007\/s12282-023-01504-y.","journal-title":"Breast Cancer"},{"issue":"68","key":"2162_CR24","doi-asserted-by":"publisher","first-page":"112712","DOI":"10.18632\/oncotarget.22521","volume":"8","author":"T Biswas","year":"2017","unstructured":"Biswas T, Efird JT, Prasad S, et al. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget. 2017;8(68):112712\u20139. https:\/\/doi.org\/10.18632\/oncotarget.22521.","journal-title":"Oncotarget"},{"issue":"3","key":"2162_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cco.2020.01.06","volume":"9","author":"T Iwamoto","year":"2020","unstructured":"Iwamoto T, Kajiwara Y, Zhu Y, et al. Biomarkers of neoadjuvant\/adjuvant chemotherapy for breast cancer. Chin Clin Oncol. 2020;9(3):27. https:\/\/doi.org\/10.21037\/cco.2020.01.06.","journal-title":"Chin Clin Oncol"},{"issue":"19","key":"2162_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jnci\/82.19.1539","volume":"82","author":"G Bonadonna","year":"1990","unstructured":"Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82(19):1539\u201345. https:\/\/doi.org\/10.1093\/jnci\/82.19.1539.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2162_CR27","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.2009.25.3286","volume":"28","author":"AS Caudle","year":"2010","unstructured":"Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(11):1821\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.25.3286.","journal-title":"J Clin Oncol"},{"key":"2162_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0540-z","volume":"13","author":"A Prat","year":"2015","unstructured":"Prat A, Fan C, Fern\u00e1ndez A, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015;13:303. https:\/\/doi.org\/10.1186\/s12916-015-0540-z.","journal-title":"BMC Med"},{"issue":"2","key":"2162_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1200\/JCO.2007.11.5352","volume":"26","author":"JS Jeruss","year":"2008","unstructured":"Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26(2):246\u201352. https:\/\/doi.org\/10.1200\/JCO.2007.11.5352.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2162_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311\u201322.","journal-title":"J Cell Physiol"},{"key":"2162_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2019.01.011","volume":"491","author":"SS Menon","year":"2019","unstructured":"Menon SS, Guruvayoorappan C, Sakthivel KM, et al. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39\u201345. https:\/\/doi.org\/10.1016\/j.cca.2019.01.011.","journal-title":"Clin Chim Acta"},{"key":"2162_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-486","volume":"11","author":"PA Fasching","year":"2011","unstructured":"Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486. https:\/\/doi.org\/10.1186\/1471-2407-11-486.","journal-title":"BMC Cancer"},{"issue":"5","key":"2162_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628\u201337. https:\/\/doi.org\/10.1038\/s41591-018-0009-7.","journal-title":"Nat Med"},{"issue":"1","key":"2162_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010204","volume":"25","author":"J Dias Nunes","year":"2023","unstructured":"Dias Nunes J, Demeestere I, Devos M. BRCA mutations and fertility preservation. Int J Mol Sci. 2023;25(1):204. https:\/\/doi.org\/10.3390\/ijms25010204.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2162_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. https:\/\/doi.org\/10.1186\/s12916-020-01817-1.","journal-title":"BMC Med"},{"issue":"2","key":"2162_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-022-06726-w","volume":"196","author":"Y Inoue","year":"2022","unstructured":"Inoue Y, Fujishima M, Ono M, et al. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer. Breast Cancer Res Treat. 2022;196(2):341\u20138. https:\/\/doi.org\/10.1007\/s10549-022-06726-w.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2162_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02520-5","volume":"13","author":"NWS Bahrin","year":"2024","unstructured":"Bahrin NWS, Matusin SNI, Mustapa A, et al. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis. Syst Rev. 2024;13(1):100. https:\/\/doi.org\/10.1186\/s13643-024-02520-5.","journal-title":"Syst Rev"},{"issue":"2","key":"2162_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/030089161410000204","volume":"100","author":"G Zhang","year":"2014","unstructured":"Zhang G, Xie W, Liu Z, et al. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer. Tumori. 2014;100(2):136\u201342. https:\/\/doi.org\/10.1177\/030089161410000204.","journal-title":"Tumori"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02162-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02162-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02162-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:11:04Z","timestamp":1783559464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02162-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2162"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02162-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}